naltrexone has been researched along with risperidone in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.56) | 18.2507 |
| 2000's | 6 (33.33) | 29.6817 |
| 2010's | 11 (61.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Dalvie, D; Loi, CM; Smith, DA | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Blatt, SD; Botash, AS; Church, CC; Jean-Louis, F; Meguid, V; Siripornsawan, MP; Weinberger, HL | 1 |
| Hunsinger, DM; Nguyen, T; Raffa, RB; Zebraski, SE | 1 |
| Dove, D; McPheeters, ML; Sathe, NA; Taylor, JL; Veenstra-VanderWeele, J; Warren, Z | 1 |
| Banga, A; Connor, DF | 1 |
| Oravecz, R; Štuhec, M | 1 |
| Findling, RL; Ji, NY | 1 |
5 review(s) available for naltrexone and risperidone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Sudden infant death syndrome, child sexual abuse, and child development.
Topics: Autistic Disorder; Child; Child Abuse, Sexual; Child, Preschool; Condylomata Acuminata; Fluoxetine; Humans; Infant; Infant, Newborn; Naltrexone; Narcotic Antagonists; Papillomaviridae; Papillomavirus Infections; Risperidone; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Sudden Infant Death | 1999 |
Is there a basis for novel pharmacotherapy of autism?
Topics: Amino Acid Sequence; Animals; Antipsychotic Agents; Autistic Disorder; Buspirone; Dietary Supplements; Humans; Immunoglobulins, Intravenous; Molecular Sequence Data; Naltrexone; Narcotic Antagonists; Risperidone; Secretin; Selective Serotonin Reuptake Inhibitors; Serotonin Receptor Agonists | 2000 |
Medications for adolescents and young adults with autism spectrum disorders: a systematic review.
Topics: Adolescent; Adult; Age Factors; Antipsychotic Agents; Child; Child Development Disorders, Pervasive; Humans; Naltrexone; Narcotic Antagonists; Risperidone; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Young Adult | 2012 |
Pharmacotherapy for mental health problems in people with intellectual disability.
Topics: Aggression; Anticonvulsants; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cognition; Human Growth Hormone; Humans; Intellectual Disability; Lithium Compounds; Mental Disorders; Methylphenidate; Naltrexone; Narcotic Antagonists; Prader-Willi Syndrome; Psychotropic Drugs; Risperidone | 2016 |
13 other study(ies) available for naltrexone and risperidone
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Which metabolites circulate?
Topics: Humans; Metabolic Clearance Rate; Pharmaceutical Preparations | 2013 |
Effectiveness of naltrexone for treating pathologic skin picking behavior in an adolescent with Prader-Willi syndrome.
Topics: Adolescent; Antipsychotic Agents; Behavior Therapy; Compulsive Behavior; Humans; Intellectual Disability; Male; Naltrexone; Narcotic Antagonists; Prader-Willi Syndrome; Psychotic Disorders; Risperidone | 2012 |
Trichotillomania successfully treated with risperidone and naltrexone: a geriatric case report.
Topics: Aged, 80 and over; Antipsychotic Agents; Female; Humans; Naltrexone; Narcotic Antagonists; Risperidone; Trichotillomania | 2014 |